Clinical and genetic characteristics of treatment-resistant asthma
https://doi.org/10.21518/2079-701X-2013-11-44-49
Abstract
Therapy resistant asthma (TRA) is most difficult to treat and its course is least predictable. TRA remains least studied despite the fact that its many mechanisms have been detected. There is still no clear definition of TRA phenotype, and the terminology has not been widely used so far. The purpose of the study was to evaluate the role of pharmacogenetic factors in therapy with glucocorticosteroids and β2-agonists in TRA patients and work out criteria for predicting therapy resistance based on genetic markers. The paper presents the results of the studies which helped to identify the phenotype of TRA taking into account its pathogenetic and clinical heterogeneity, to determine predictors of the disease and establish uniform criteria for diagnosis taking into account genetic determinants.
About the Authors
V. I. Trofimov
Saint Petersburg State Medical University named after I.P. Pavlov
Russian Federation
Russian Federation
G. A. Mironova
Saint Petersburg State Medical University named after I.P. Pavlov
Russian Federation
Russian Federation
References
1. Braman S.S. The global burden of asthma. Chest, 2006; 130: 4-12.
2. Demoly P., Gueron B., Annuziata K.et al. Update on asthma control in five European countries: results of a 2008 survey. Eur.Resp.Rev.2010; 19(116): 150e7.
3. Архипов В.В., Григорьева Е.В., Гаврилина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА, Пульмонология, 2011, 6: 87-93.
4. Петровский В.Ф., Огородова Л.М. Выбор фармакотерапии тяжелой БА // Пульмонология.- 2008.- №3.-С.84-89.
5. Barnes K.S., Marsh D.G. The genetics and complexity of allergy and asthma // Immunol.Today.-1998.-Vol.19.-P. 325-332.
6. Огородова Л. М., Петровский Ф. И., Петровская Ю. А. Сложная астма // Пульмонология . - 2001.-№ 1.-С. 94-100.
7. Wenzel S. Severe Asthma in Adults // Am J Respir Crit Care Med.- 2005.-№ 172.-P. 149–160.
8. Chung K.F., Bel E.H., Wenzel S.E. Difficult-to-treat severe asthma // European respiratory monograph.- March 2011.- N51.-P. 308.
9. Пузырев В.П., Огородова Л.М. Генетика бронхолегочных заболеваний // Под ред. А.Г. Чучалина.-М. «Атмосфера».-2010.-С.160.
10. Hawkins G.A., Amelung P.J., Richard S. Smith. et al. Identification of Polymorphisms in the Human Glucocorticoid Receptor Gene ( NR3C1 ) in a Multi-racial Asthma Case and Control Screening Panel // J. DNA Seq. – 2004.-Vol.15.-№ 3.-P.167-173.
11. Contopoulos-Ioannidis, D.G.; Manoli, E.N.; Ioannidis, J.P. Meta-analysis of the association of beta-2-adrenergic receptor polymorphisms with asthma phenotypes // J. Allergy Clin. Immun.- 2005.-Vol.115.-P. 963-972.
12. Hall I.P., Sayers I. Phamacogenetics and asthma: false hope or new dawn? // Eur Respir J.- 2007.-№ 29.-Р. 1239-1245.
13. Farrell R.O., Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. // Journal of Endocrinology.- 2003.-Vol. 178.-P. 339-346.
14. Gagliardo R., Chanes P., Vignola A.N., et. al. Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma // Amer. J. of Respir. and Critical Care Medicine.-2000-Vol.162.-P. 7-13.
15. Whorwood C.B., Donovan S.J., Wood P.J., Regulation of glucocrticoid receptorα and β isoforms and type I 11β-hydroxysteroid dehydrogenase axpression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? // J Clin Endocrinol Metab.- 2001.-Vol. 86.-P. 2296-2308.
16. Goleva E., Li L., Eves P. et al. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma // Am. J. Respir. Crit. Care Med. – 2006. – Vol.173. -P.607-616.
17. Фрейдин М.Б., Пузырев В.П., Огородова Л.М., Кобякова О.С., Кулманакова И.М. Полиморфизм генов интерлейкинов и их рецепторов: популяционная распространенность и связь с атопической бронхиальной астмой // Генетика. -2002.-Том38.- №12.-С. 1-9.
18. Келембет Н.А., Гембицкая Т.Е., Иващенко Т.Э., Лаврова О.В. Ассоциация полиморфизма генов IL4 и IL4Rα с развитием аллергической бронхиальной астмы // Болезни органов дыхания. -2008. - №1.- С.36-41.
19. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions // Am J Respir Crit Care Med.-2000.-Vol.162.- P. 2341–2351.
20. Маниатис Т., Фрич Э., Сэмбрук Д. Методы генетической инженерии. Молекулярное клонирование. – М.: Мир, 1984. – С. 480.
21. Newton R., Leigh R., Giembycz M.A. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung disease. // Pharmacology&Therapeutics.- 2010.-Vol. 125.-P. 286-327.
22. Comerford K.M., Wallace T.J., Karhausen J, Louis N.A. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance gene (MDR1) // Cancer Res.- June 15.-2002.-Vol. 62.-P. 3387.
23. Zarickii А.U., Bikova Т.V., Lomaia Е.G. et al. K-562 transfected with MDR-1 gene are less sensetiv than parental cells to interferon-alpha induced inhibition of cell proliferation // Acta Haematologyca.- 1998.-Vol. 100 (1).-P. 231.
24. Зубова С.Г., Данилов А.О., Мышков А.И. Ген MDR1 и чувствительность клеток к различным воздействиям. // Вопросы онкологии.- 2000.- Т. 46.- №2.-C. 199.
25. Кетлинский С.А., Симбирцев А.С. Цитокины // СПб. -Фолиант.-2008. С. 550.
26. Wills-Karp M., Chiaramonte M. Interleukin-13 in asthma // Curr Opin Pulm.- 2003.-Med 9(1).-P. 21-27.
27. Barnes P.J., Drazen J.M., Rennard S.I., Thomson N.C. Asthma and COPD. Basic mechanism and clinical management. Second edition.- Elsevier- 2009.
28. Jakiela B., Bochenek G., Sanak M. //Glucocorticoid receptor isoforms in steroid-dependent asthma. Polskie archiwum medycyny wewnetrznej .-2010.-Vol.120 (6).-P. 214-221.
29. Pavord J.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, donble-blind, placebo-controlled trial. The Lancet, 2012; 308:651-659.
30. Corren J., Lemenske R.F., Hanania N.A. et al. Lebrikizumab treatment in adults with asthma. N. Engl.J.Med . 2011; 365: 1088-1098.
31. Piper E., Briyhtling C., Niven R. et.al. A phase II placebo-controlled study of tralokinumab in moderate –to-severe asthma. Eur. Resp.J. 2013; 41: 330-338.
Review
For citations:
Trofimov VI, Mironova GA. Clinical and genetic characteristics of treatment-resistant asthma. Meditsinskiy sovet = Medical Council. 2013;(11):44-49. (In Russ.) https://doi.org/10.21518/2079-701X-2013-11-44-49
Views:
405
Email this article 